Definium Therapeutics (NASDAQ:DFTX) Given "Overweight" Rating at Piper Sandler

Key Points

• Piper Sandler reaffirmed an “overweight” rating on Definium Therapeutics and raised its price target to $75 from $73, implying 65.86% potential upside from the prior close. The analyst consensus remains “Buy,” with an average target of $55.
• DFTX shares fell 2.0% to $45.22, while the company reported a quarterly loss of $1.44 per share—$0.89 worse than analysts’ expected loss of $0.55.
• Insiders have sold 48,096 shares worth approximately $2.17 million over the past 90 days, while institutional investors own 27.91% of the company.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report)'s stock had its "overweight" rating reissued by research analysts at Piper Sandler in a research report issued on Friday,Benzinga reports. They presently have a $75.00 price target on the stock, up from their previous price target of $73.00. Piper Sandler's price target suggests a potential upside of 65.86% from the company's previous close.

Several other research firms have also recently issued reports on DFTX. Wells Fargo & Company initiated coverage on Definium Therapeutics in a research note on Monday, July 27th. They set an "overweight" rating and a $68.00 target price on the stock. Robert W. Baird lifted their price target on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, June 23rd. Citigroup reissued a "buy" rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Definium Therapeutics in a report on Friday, July 17th. Finally, Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an "outperform" rating in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Definium Therapeutics currently has a consensus rating of "Buy" and an average price target of $55.00.

Definium Therapeutics Trading Down 2.0%

Shares of Definium Therapeutics stock traded down $0.92 during trading on Friday, reaching $45.22. 1,534,675 shares of the stock were exchanged, compared to its average volume of 2,250,882. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of -18.16 and a beta of 2.23. Definium Therapeutics has a 1 year low of $8.70 and a 1 year high of $49.70. The stock's fifty day moving average is $37.45 and its 200 day moving average is $25.72.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, equities research analysts expect that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This trade represents a 1.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the business's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider directly owned 174,633 shares in the company, valued at $7,863,723.99. The trade was a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,096 shares of company stock worth $2,165,763 in the last ninety days. 2.40% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DFTX. Cerity Partners LLC boosted its holdings in shares of Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company's stock valued at $322,000 after acquiring an additional 1,165 shares during the last quarter. Creative Planning raised its stake in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company's stock valued at $429,000 after buying an additional 1,655 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock valued at $259,000 after buying an additional 2,079 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock worth $315,000 after buying an additional 2,342 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source